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Analysis ofthe binding specificity ofreceptor chimeras through
use of A( AG) values for pairs of agonist or antagonist drugs
allows a linear comparison of the relative contributions of dif-
ferent receptor domains to receptor binding specificity ( 1, 2).
This method was first applied to the data set of Kobilka et al.
(3) on chimeras between ,B-adrenergic and a2-adrenergic recep-
tors, one of the first reports to use the chimeric-receptor ap-
proach to analyze the contributions of multiple transmem-
brane domains to receptor binding specificity. The data set of
Kobilka et al. (3) was not ideal for this analysis because it
included both comparisons ofK, values for competitive inhibi-
tion ofligand binding and EC50 values for activation ofadenyl-
ate cyclase. Jackson (2) is correct in pointing out that these two
values can differ substantially for agonists activating adenylate
cyclase and therefore should not generally be mixed together in
a quantitative analysis. However, A( AG) values are calculated
from the ratio oftwo Ki values or two EC,0 values; for agonists
of similar efficacy, these ratios will be similar. Indeed, the con-
sideration of A(AG) values, which depend only on ratios of
apparent Kd values as previously proposed (1), substantially
simplifies the assumptions that must be made in analyzing
changes in relative binding specificity as pointed out by Jack-
son (2).
In applying this method to the data set of Kobilka et al. (3)
for relative affinity of isoproterenol (ISO) and p-amino cloni-
dine (PAC) for receptor chimeras, the same tentative conclu-
sion is reached whether ratios of Ki values from competitive
binding data are considered alone or together with ratios of
EC50 values for chimeric receptor 6: transmembrane segments
1 through 5 each make an important contribution of -0.8
kcal/mol to the value of A(AG), but transmembrane segment
7 makes a much more substantial contribution of -3.7 kcal/
mol (1). These published data suggest that transmembrane
segment 7 has a unique role in determining the binding specific-
ity for these two ligands ( 1, 3). This conclusion would be sub-
stantially strengthened by a more complete analysis ofthe bind-
ing affinities of these two ligands for additional chimeras in
which each transmembrane segment is exchanged in a step-
wise manner. Data for such an analysis are not available at
present. However, a recent report (4) shows that a single resi-
due in the seventh transmembrane segment determines the
binding specificity ofyohimbine and related a2 receptor antago-
nists in agreement with the conclusions of the previous work.
Epinephrine is a physiological ligand for both a2- and /3-
adrenergic receptors. Although it binds with higher affinity to
a2 receptors, it is not nearly as selective as ISO or PAC. Jackson
(2) shows by analysis of the results of Kobilka et al. (3) using
A(AG) values that each transmembrane segment contributes
approximately equivalently to the binding specificity for epi-
nephrine and ISO. One may expect that the determinants of
binding selectivity for different classes of ligands will reside in
distinct chemical interactions with different functional groups
in or near the agonist binding sites of receptors. Evidently, the
binding interactions which determine the selectivity ofepineph-
rine and PAC for these two receptors are distinct, as one would
predict from their different structures and specificity ratios.
Analysis of A(AG) values for binding of receptor-specific
ligands to chimeras of,1 and #2-adrenergic receptors synthe-
sized in a bacterial expression system led to the conclusion that
all seven transmembrane segments contribute to the binding
specificity ofthese two adrenergic receptors and that the contri-
bution of individual transmembrane segments varies depend-
ing on the specific ligand (5). Altogether, the experimental
results analyzed by comparison of A(AG) values for ligand
binding to the family of adrenergic receptors argue that all
transmembrane segments are involved in determination of
binding specificity. Transmembrane segment 7 has a special
role in binding ligands of specific structural classes. The use of
A( AG) values as a parameter for comparison (1) helps to sim-
plify and clarify these complex analyses.
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